AU2022290378B2 - Autotaxin (atx) inhibitor for the treatment of pancreatic cancer - Google Patents
Autotaxin (atx) inhibitor for the treatment of pancreatic cancerInfo
- Publication number
- AU2022290378B2 AU2022290378B2 AU2022290378A AU2022290378A AU2022290378B2 AU 2022290378 B2 AU2022290378 B2 AU 2022290378B2 AU 2022290378 A AU2022290378 A AU 2022290378A AU 2022290378 A AU2022290378 A AU 2022290378A AU 2022290378 B2 AU2022290378 B2 AU 2022290378B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- salt
- pancreatic cancer
- gemcitabine
- used according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2108245.8 | 2021-06-09 | ||
| GBGB2108245.8A GB202108245D0 (en) | 2021-06-09 | 2021-06-09 | Methods of treatment |
| PCT/EP2022/065562 WO2022258693A1 (en) | 2021-06-09 | 2022-06-08 | Autotaxin (atx) inhibitor for the treatment of pancreatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022290378A1 AU2022290378A1 (en) | 2024-01-04 |
| AU2022290378B2 true AU2022290378B2 (en) | 2026-06-11 |
Family
ID=76838834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022290378A Active AU2022290378B2 (en) | 2021-06-09 | 2022-06-08 | Autotaxin (atx) inhibitor for the treatment of pancreatic cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250057820A1 (enExample) |
| EP (1) | EP4351563A1 (enExample) |
| JP (1) | JP2024522135A (enExample) |
| CN (1) | CN117295496A (enExample) |
| AU (1) | AU2022290378B2 (enExample) |
| CA (1) | CA3218103A1 (enExample) |
| GB (1) | GB202108245D0 (enExample) |
| MX (1) | MX2023014637A (enExample) |
| WO (1) | WO2022258693A1 (enExample) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016124939A1 (en) * | 2015-02-06 | 2016-08-11 | Cancer Research Technology Limited | Autotaxin inhibitory compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9850203B2 (en) * | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| JP2024511836A (ja) * | 2021-03-29 | 2024-03-15 | アイオンクチュラ・ソシエテ・アノニム | 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤 |
-
2021
- 2021-06-09 GB GBGB2108245.8A patent/GB202108245D0/en not_active Ceased
-
2022
- 2022-06-08 JP JP2023574275A patent/JP2024522135A/ja active Pending
- 2022-06-08 WO PCT/EP2022/065562 patent/WO2022258693A1/en not_active Ceased
- 2022-06-08 AU AU2022290378A patent/AU2022290378B2/en active Active
- 2022-06-08 US US18/567,932 patent/US20250057820A1/en active Pending
- 2022-06-08 MX MX2023014637A patent/MX2023014637A/es unknown
- 2022-06-08 CN CN202280032188.0A patent/CN117295496A/zh active Pending
- 2022-06-08 CA CA3218103A patent/CA3218103A1/en active Pending
- 2022-06-08 EP EP22734239.1A patent/EP4351563A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016124939A1 (en) * | 2015-02-06 | 2016-08-11 | Cancer Research Technology Limited | Autotaxin inhibitory compounds |
Non-Patent Citations (1)
| Title |
|---|
| BURRIS, H. A. ET AL.: "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial", J CLIN ONCOL 91997) vol. 15, pages 2403-2413 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022290378A1 (en) | 2024-01-04 |
| WO2022258693A1 (en) | 2022-12-15 |
| EP4351563A1 (en) | 2024-04-17 |
| MX2023014637A (es) | 2024-01-31 |
| GB202108245D0 (en) | 2021-07-21 |
| JP2024522135A (ja) | 2024-06-11 |
| CA3218103A1 (en) | 2022-12-15 |
| US20250057820A1 (en) | 2025-02-20 |
| CN117295496A (zh) | 2023-12-26 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: IONCTURA BV Free format text: FORMER APPLICANT(S): IONCTURA SA |